Drugs / Apornemin
last change Jun 2026 re-read 2 minutes ago

Apornemin

Developed for
plasma cell myeloma
Investigated by
Institute of Hematology & Blood Diseases Hospital, China

Trials 1 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
NCT06793475 Apr 2025 → Jun 2026 overdue plasma cell myeloma Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Apornemin ClinicalTrials.gov intervention name — accepted as the source's own label NCT06793475
Route Intravenous “Apornemin 10mg/kg will be administered by i.v. infusion.” NCT06793475